Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1997 2
1998 5
1999 1
2001 1
2006 5
2007 1
2008 3
2009 5
2011 3
2012 9
2013 7
2014 8
2015 2
2016 5
2017 8
2018 4
2019 4
2020 6
2021 3
2022 2
2023 4
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Among authors: von dem borne pa. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
[Skin disorders associated with monoclonal gammopathies].
Houtman CJ, Genders RE, von dem Borne PA, Vermeer MH. Houtman CJ, et al. Among authors: von dem borne pa. Ned Tijdschr Geneeskd. 2014;158:A6717. Ned Tijdschr Geneeskd. 2014. PMID: 24780569 Review. Dutch.
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Baron F, Labopin M, Versluis J, Vydra J, von dem Borne PA, Nicholson E, Blaise D, Protheroe R, Kulagin A, Bulabois CE, Rovira M, Chevallier P, Forcade E, Byrne J, Sanz J, Ruggeri A, Mohty M, Ciceri F. Baron F, et al. Among authors: von dem borne pa. Am J Hematol. 2024 Dec;99(12):2296-2305. doi: 10.1002/ajh.27466. Epub 2024 Aug 31. Am J Hematol. 2024. PMID: 39215605
Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, Halkes CJM, de Wreede LC. Koster EAS, et al. Among authors: von dem borne pa. Front Immunol. 2024 Mar 13;15:1335341. doi: 10.3389/fimmu.2024.1335341. eCollection 2024. Front Immunol. 2024. PMID: 38545096 Free PMC article.
The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
von dem Borne PA, Kemps-Mols BM, de Wreede LC, van Beek AA, Snijders TJF, van Lammeren D, Tijmensen J, Sijs-Szabó A, Oudshoorn MA, Halkes CJM, van Balen P, Marijt WAE, Tjon JML, Vermaat JSP, Veelken H. von dem Borne PA, et al. Leuk Lymphoma. 2024 Sep;65(9):1270-1280. doi: 10.1080/10428194.2024.2344060. Epub 2024 May 6. Leuk Lymphoma. 2024. PMID: 38710017 Free article.
Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients.
van der Zouwen B, Koster EAS, von dem Borne PA, Oosten LEM, Roza-Scholten MWI, Snijders TJF, van Lammeren D, van Balen P, Marijt WAF, Veelken H, Falkenburg JHF, de Wreede LC, Halkes CJM. van der Zouwen B, et al. Among authors: von dem borne pa. Ann Hematol. 2023 May;102(5):1203-1213. doi: 10.1007/s00277-023-05145-1. Epub 2023 Mar 7. Ann Hematol. 2023. PMID: 36881136 Free PMC article.
Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS, von dem Borne PA, van Balen P, van Egmond EHM, Marijt EWA, Veld SAJ, Jedema I, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, de Wreede LC, Halkes CJM. Koster EAS, et al. Among authors: von dem borne pa. Transplant Cell Ther. 2023 Apr;29(4):268.e1-268.e10. doi: 10.1016/j.jtct.2022.12.022. Epub 2022 Dec 30. Transplant Cell Ther. 2023. PMID: 36587743 Free article.
84 results